Clock's ticking, Teva, as far as deal target Mylan's concerned. The Israeli drugmaker needs to either "stop playing games" and turn its $40 billion approach into a formal bid--or walk.
Juno Therapeutics, at work on immune system-harnessing cancer treatments, bought up a small Massachusetts biotech to further flesh out its arsenal of technologies, picking up a new discovery platform as it races toward late-stage trials.
Steris and Synergy said they will fight the U.S. Federal Trade Commission's plan to prevent their $1.9 billion merger, which would create a global powerhouse in the medical device sterilization sector.
Orphan drugs are attractive to make thanks to premium pricing prospects, limited competition and regulatory perks. But those factors also make them attractive to buy, and they'll continue to spur M&A activity in the biopharma field, Moody's predicts.
After having to call off a $1.5 billion deal last year to sell its U.S.-based generics business, Belgium's UCB has new bidders for the unit that reportedly includes India's Cipla and Lupin.
Zimmer already has clearances from regulators in Europe and Japan for its proposed $13.4 billion acquisition of Biomet. Now it's close to gaining the go-ahead from the U.S. Federal Trade Commission. Zimmer has disclosed that it has secured buyers for three U.S. businesses to satisfy FTC requests: Zimmer Unicompartmental High-Flex Knee System assets, Biomet Discovery Elbow System assets and Cobalt bone cement assets.
Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.
Bayer has seen many an M&A opportunity come and go when it comes to bolstering its animal health unit. But once it jettisons its plastics unit--a move that could generate some extra dough--it might finally be ready to strike a deal.
Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.
French medical diagnostics outfit Labco is selling out to U.K. private equity firm Cinven for €1.2 billion ($1.3 billion), shifting gears after abandoning its previously announced IPO.